Castle Biosciences (CSTL) Other Non-Current Liabilities (2019 - 2026)

Castle Biosciences has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $1.5 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $1.5 million for Q1 2026 at Castle Biosciences, roughly flat from $1.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.5 million in Q2 2025 to a low of $16000.0 in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $100000.0 (2022), against an average of $511615.4.
• Across the five-year window, Other Non-Current Liabilities jumped 4033.33% in 2022 and sank 72.22% in 2023, its largest moves.
• Castle Biosciences' Other Non-Current Liabilities stood at $90000.0 in 2022, then tumbled by 72.22% to $25000.0 in 2023, then tumbled by 36.0% to $16000.0 in 2024, then jumped by 9275.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.